Recent 8-K filings for XOMA

• May 22, 2026, 6:01 AM ET other material materiality 0.50 neutral item 5.02item 5.03item 5.07item 9.01 ◈ Governance Changes

  XOMA Royalty stockholders approve equity plan amendments, new ESPP, and bylaw forum provision

  Stockholders approved amendment to 2010 Long Term Incentive Plan, increasing share reserve by 425,000 and extending term to 2036.

• May 18, 2026, 9:11 AM ET other material materiality 0.30 neutral item 1.01item 9.01

  XOMA Royalty amends merger agreement to add newly formed holding company for Ligand acquisition

  HoldCo (XOMA Royalty Holdings Corporation) formed on May 15, 2026 and added as party to the Merger Agreement with Ligand Pharmaceuticals.

• April 27, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 2.01item 8.01item 9.01

  XOMA completes Generation Bio acquisition; estimates CVR value at $0.81/share

  XOMA paid $4.2913 per share cash plus one non-tradeable CVR for Generation Bio; ~70% of shares tendered.

• April 27, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01item 8.01item 9.01 ◈ Material Agreements

  Ligand to acquire XOMA Royalty for $39.00/share cash plus contingent value rights

  Per-share consideration: $39.00 cash plus CVRs representing rights to 75% of net proceeds from Janssen litigation.

• March 18, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY

  Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.

• March 2, 2026, 6:59 PM ET other material materiality 0.30 neutral item 2.02item 7.01item 9.01

  XOMA Royalty releases updated corporate presentation; financial data on pages 10-11 not extractable from exhibit snippet

  Filed March 2, 2026: updated corporate presentation made available as Exhibit 99.1.

• February 9, 2026, 6:59 PM ET M&A materiality 0.75 neutral item 2.01item 8.01item 9.01 ◈ M&A Transactions

  XOMA Royalty closes acquisition of Generation Bio for $4.2913/share plus CVR

  Completed tender offer; 4,722,533 shares (approx. 70%) tendered, all accepted.

• February 2, 2026, 6:59 PM ET M&A materiality 0.65 neutral item 2.01item 8.01item 9.01 ◈ M&A Transactions

  XOMA completes acquisition of LAVA legacy assets; details Pfizer, Janssen programs and CVR terms

  XOMA completed acquisition of LAVA legacy assets (EGFRd2, JNJ-89853413, LAVA-1266) on Nov 20, 2025.

• January 15, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02item 7.01item 9.01

  XOMA Royalty names Jeffrey Trigilio CFO; Thomas Burns departs after ~19 years

  Thomas Burns stepped down as CFO effective Jan 12, 2026; separation agreement includes $16k/month consulting for 3 months.

• January 12, 2026, 6:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  XOMA Royalty posts updated corporate presentation; no specific material changes disclosed

  Filed updated corporate presentation on Form 8-K dated January 12, 2026 (Exhibit 99.1).

• December 5, 2025, 6:59 PM ET M&A materiality 0.70 neutral item 2.01item 8.01item 9.01

  XOMA Royalty completes acquisition of Mural Oncology for $2.035/share

  Deal closed Dec 5, 2025; Mural shareholders received $2.035 cash per share.

• November 21, 2025, 6:59 PM ET M&A materiality 0.60 neutral item 2.01item 8.01item 9.01 ◈ M&A Transactions

  XOMA completes acquisition of LAVA Therapeutics for $1.04/share plus CVRs

  Subsequent Offering Period expired Nov 20, 2025; Post-Offer Reorganization effective same day.

• November 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  XOMA Royalty Q3 net income $14.1M vs loss $17.2M; revenue $9.4M; cash receipts $43.9M YTD

  Net income of $14.1M in Q3 2025, compared to net loss of $17.2M in Q3 2024.

• October 3, 2025, 7:59 PM ET other materiality 0.65 neutral item 1.01item 9.01

  XOMA enters ATM sales agreements for up to $125M in common stock and preferred depositary shares

  Up to $75M common stock ATM with Leerink Partners; 3% commission.

• September 26, 2025, 7:59 PM ET other materiality 0.02 neutral item 5.03item 9.01 ◈ Governance Changes

  XOMA corrects typo in Series B preferred stock certificate of designation

  Certificate of Correction filed Sept 23, 2025 for Series B Cumulative Perpetual Preferred Stock.

• September 23, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 2.01item 8.01item 9.01

  XOMA completes acquisition of HilleVax for $1.95 per share plus CVR

  XOMA acquired HilleVax via tender offer and merger; offer price of $1.95 cash plus one CVR per share.

• August 15, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 2.01item 8.01item 9.01 ◈ M&A Transactions

  XOMA completes acquisition of Turnstone Biologics for $0.34 cash plus CVR per share

  XOMA accepted 17,192,002 shares (~74% of outstanding) at $0.34 plus one CVR per share.

• August 13, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  XOMA Royalty Q2 net income $9.2M; acquires Turnstone, HilleVax, LAVA; H1 cash receipts $29.6M

  Net income $9.2M (Q2 2025) vs $16.0M (Q2 2024); income & revenue $13.1M vs $11.1M.

• May 30, 2025, 7:59 PM ET other material materiality 0.50 neutral item 3.03item 5.02item 5.03item 5.07item 9.01

  XOMA stockholders approve reincorporation to Nevada and increase in equity plan shares by 880,000

  Reincorporation from Delaware to Nevada effective May 30, 2025; no change in business, management, or assets.

• May 13, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  XOMA Royalty Q1 net income $2.4M, total revenues $15.9M; adds Castle Creek royalty, sells Kinnate assets

  Q1 2025 total revenues $15.9M (vs $1.5M Q1 2024); net income $2.4M (vs net loss $8.6M).

• March 17, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets

  Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.

• February 11, 2025, 6:59 PM ET M&A materiality 0.75 neutral item 9.01

  XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024

  XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.

• December 2, 2024, 6:59 PM ET M&A materiality 0.75 positive item 8.01item 9.01

  XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest

  Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired

  Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.

• October 22, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  XOMA Royalty acquires 50% of Twist Bioscience's royalty/milestone economics for $15M

  Acquired 50% economic interest in milestones/royalties from Twist's 60+ early-stage programs across 30 partners for $15M upfront.

• September 23, 2024, 7:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  FDA approves Zevra's MIPLYFFA for NPC; XOMA holds royalty on sales up to $52.6M milestones

  FDA approved MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on Sept 20, 2024.

• August 13, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  XOMA Royalty Q2 net income $16.0M; receives $22.6M cash; acquires Kinnate and Daré rights; posts $9.0M impairment

  Net income $16.0M vs net loss $5.4M in Q2 2023; total income/revenue $11.1M; cash receipts $22.6M.

• July 9, 2024, 7:59 PM ET other material materiality 0.20 neutral item 5.03item 9.01

  XOMA Corporation changing name to XOMA Royalty Corporation on July 10, 2024

  Name change effective 12:01 a.m. ET on July 10, 2024; ticker 'XOMA' and CUSIP unchanged.

• June 13, 2024, 7:59 PM ET M&A materiality 0.80 negative item 9.01

  XOMA closes Kinnate acquisition for $122.7M cash; Q1 2024 pro forma net loss $21.7M

  Cash consideration of $2.5879 per share + one CVR; aggregate cash $122.7M financed from cash on hand.

• May 30, 2024, 7:59 PM ET other material materiality 0.55 positive item 8.01

  XOMA to receive $8.1M from Viracta after Day One sells PRV for $108M

  Day One Biopharmaceuticals sold a priority review voucher for $108M after FDA approval of OJEMDA.

• May 16, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  XOMA shareholders elect all seven director nominees and ratify Deloitte as auditor

  All seven director nominees elected with >99% votes for (excluding broker non-votes).

• May 9, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  XOMA Q1 net loss $8.6M; FDA approves OJEMDA triggering $9M milestone

  Q1 revenue $1.5M (vs $0.4M YoY) on $1M AVEO milestone; net loss $8.6M (vs $9.8M YoY).

• April 30, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  XOMA pays $22M upfront for royalty interests in three women's health assets from Daré Bioscience

  XOMA paid $22M cash to Daré for royalties on XACIATO, Ovaprene, and Sildenafil Cream.

• April 25, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  XOMA earns $9M milestone on FDA approval of Day One's OJEMDA for pediatric low-grade glioma

  XOMA earned $9M milestone from FDA accelerated approval of Day One's OJEMDA (tovorafenib) for relapsed/refractory BRAF-altered pLGG.

• April 3, 2024, 7:59 PM ET M&A materiality 0.90 neutral item 2.01item 8.01item 9.01 ◈ M&A Transactions

  XOMA completes acquisition of Kinnate Biopharma for $2.5879 per share plus CVRs

  XOMA purchased ~81% of Kinnate shares via tender offer at $2.5879/share plus one CVR per share.

• March 8, 2024, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  XOMA reports Q4 2023 net loss $20.1M, revenue $1.8M; cash $159.6M

  Full year 2023 net loss $40.8M vs $17.1M in 2022; revenue $4.8M vs $6.0M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.70 · Most common event m_and_a

13 positive 2 negative 21 neutral

source · XOMA on sec.gov